このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Mind Medicine (MindMed) 配当金

配当金基準チェック /06

Mind Medicine (MindMed)配当金を支払った記録がありません。

主要情報

n/a

配当利回り

n/a

配当性向

業界平均利回り	2.1%
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
一株当たり利益	-US$1.25
3年後の配当利回り予想	n/a

最近の配当金アップデート

更新なし

Recent updates

Psychedelic Stocks: Focus On Their Cash

Aug 15

MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors

Jun 05

Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data

Apr 04

Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts

Feb 02

Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans

May 23

We're Hopeful That Mind Medicine (MindMed) (NASDAQ:MNMD) Will Use Its Cash Wisely

Feb 07

MindMed: Not The Horse To Back If You're Looking To Buy Psychedelics

Oct 19

MindMed announces proposed public offering of common shares

Sep 27

MindMed doses first patient in phase 1 trial examining psychedelic MDMA-like substances

Sep 20

MindMed regains compliance with Nasdaq's minimum bid price listing requirement

Sep 14

MindMed: Confusing MEME Rally Hides A Company That Looks Empty Of Value

Sep 04

Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans

Aug 26

Magic mushrooms psychedelic compound can help with treatment of alcohol use disorder

Aug 24

MindMed soars 71% as it appears to be following in Bed Bath & Beyond's footsteps

Aug 18

決済の安定と成長

配当データの取得

安定した配当: MNMDの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: MNMDの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Mind Medicine (MindMed) 配当利回り対市場

MNMD 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (MNMD)	n/a
市場下位25% (US)	1.4%
市場トップ25% (US)	4.4%
業界平均 (Pharmaceuticals)	2.1%
3年後のアナリスト予想 (MNMD)	n/a

注目すべき配当: MNMDは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: MNMDは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: MNMDの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: MNMDが配当金を報告していないため、配当金の持続可能性を計算できません。

Mind Medicine (MindMed) 配当金

配当金 基準チェック /06

主要情報

最近の配当金アップデート

Recent updates

Executive President exercised options and sold US$81k worth of stock

Mind Medicine (Mindmed) Inc. Presents Phase 2B Study of Mm120 for Generalized Anxiety Disorder (Gad) At American Psychiatric Association

Psychedelic Stocks: Focus On Their Cash

Mind Medicine (MindMed) Inc. has completed a Follow-on Equity Offering in the amount of $74.998573 million.

Mind Medicine (MindMed) Inc. has filed a Follow-on Equity Offering.

Mind Medicine (MindMed) Inc. to Report Q2, 2024 Results on Aug 13, 2024

Mindmed Appoints Stephanie Fagan as Chief Corporate Affairs Officer

Mind Medicine (MindMed) Inc. Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)

Mind Medicine (MindMed) Inc.(NasdaqGS:MNMD) dropped from Russell 3000E Value Index

Mind Medicine (MindMed) Inc Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors

Mind Medicine (MindMed) Inc., Annual General Meeting, Jun 10, 2024

Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data

Numinus Wellness Congratulates Mindmed on Positive Results from Phase 2B Clinical Trials of Mm120 for Generalized Anxiety Disorder

New major risk - Shareholder dilution

Mind Medicine (MindMed) Inc. has completed a Follow-on Equity Offering in the amount of $100.000002 million.

Price target increased by 10% to US$28.67

Mind Medicine (MindMed) Inc. announced that it expects to receive $75 million in funding from Deep Track Capital, LP, Commodore Capital

Mind Medicine (MindMed) Inc. has completed a Follow-on Equity Offering in the amount of $100.000002 million.

Price target increased by 7.5% to US$26.17

Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts

Mind Medicine (Mindmed) Inc. Provides Anticipated Production Milestones for 2024

Mind Medicine Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

New minor risk - Share price stability

Price target increased by 14% to US$25.83

Price target decreased by 36% to US$14.50

New major risk - Revenue and earnings growth

Price target increased by 14% to US$25.83

New minor risk - Market cap size

Mind Medicine (MindMed) Inc. Completes Enrollment of Phase 2A Trial of Mm-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)

Mind Medicine Completes Enrollment and Dosing in Study Mmed008

Chief Financial Officer recently sold US$76k worth of stock

New minor risk - Share price stability

Mind Medicine (Mindmed) Inc. Elects David Gryska to the Board of Directors

FCM MM Holdings Posts Material on Social Media Platforms

FCM MM Holdings Calls for Socially Responsible Investors to Vote for Change at Mind Medicine

FCM MM Holdings Posts Material on Twitter

FCM MM Holdings Provides Information to Shareholders of Mind Medicine

FCM MM Holdings Condemns the Report Issued by Institutional Shareholder Services

FCM MM Holdings LLC Issues a Letter to the Shareholders of Mind Medicine Inc

FCM MM Holdings Posts Materials to Reddit

FCM MM Holdings Sends Letter to Shareholders of Mind Medicine (MindMed)

Mind Medicine Posts Materials to Twitter

FCM MM Holdings Issues an Investor Presentation to Shareholders of Mind Medicine

Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans

Mind Medicine (MindMed) Inc. Enters into Phase 2b Clinical Trial Evaluating MM-120 (lysergide D-Tartrate) for GAD

FCM Director Nominees Will Put MindMed Drug Development Process Back on Track

Mind Medicine Launches a Website and Post the Materials

Mind Medicine (MindMed) Inc., Annual General Meeting, Jun 15, 2023

We're Hopeful That Mind Medicine (MindMed) (NASDAQ:MNMD) Will Use Its Cash Wisely

Price target decreased by 11% to US$27.63

High number of new and inexperienced directors

FCM MM Holdings LLC Sends a Letter to Mind Medicine (MindMed) Inc

FCM MM HOLDINGS, LLC Demands Federal Investigation to Probe Serious Allegations of Misconduct at Mind Medicine (MindMed) Inc

MindMed: Not The Horse To Back If You're Looking To Buy Psychedelics

Mind Medicine Announces Initiation of Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA

FCM MM HOLDINGS Sends Letter to the Board of Mind Medicine

MindMed announces proposed public offering of common shares

Mind Medicine (MindMed) Inc. Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances

Price target decreased to US$51.10

MindMed doses first patient in phase 1 trial examining psychedelic MDMA-like substances

Mind Medicine Regains Compliance with Nasdaq's Minimum Bid Price Listing Requirement

MindMed regains compliance with Nasdaq's minimum bid price listing requirement

Mind Medicine (MindMed) Inc. Announces Positive Results from Collaborators' Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal

MindMed: Confusing MEME Rally Hides A Company That Looks Empty Of Value

Mind Medicine (MindMed) Inc. Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

Mind Medicine (MindMed) (NASDAQ:MNMD) Is In A Good Position To Deliver On Growth Plans

Magic mushrooms psychedelic compound can help with treatment of alcohol use disorder

MindMed soars 71% as it appears to be following in Bed Bath & Beyond's footsteps

Mind Medicine (MindMed) Inc. Announces Board Appointments

Mind Medicine GAAP EPS of -$0.04 beats by $0.01

Mind Medicine announces 1-for-15 reverse stock split

MindMed: Another Psychedelic Medicine Play Trading At A Potential Discount

Mind Medicine (MindMed) Receives Non-Compliance Letter from Nasdaq

Mind Medicine (MindMed) Inc. Appoints Schond L. Greenway as Chief Financial Officer

配当金基準チェック /06